Neuroendocrine Tumors
Conditions
Keywords
PNET, GI-NET, neuroendocrine, carcinoid
Brief summary
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or Gastrointestinal Neuroendocrine tumors (GI-NETs) with elevated biochemical markers who have relapsed during or after receiving prior standard of care therapies, including octreotide, chemotherapy or targeted therapy.
Detailed description
Subjects enrolled in this PNET/GI-NET study (OX4218s) will receive weekly dosing with fosbretabulin for up to 3 cycles or approximately 9 weeks.
Interventions
60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
Sponsors
Mateon Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to read, understand and provide written consent to participate in the study * Age ≥ 18 years * Biopsy-proven well-differentiated, low-to-intermediate-grade PNET or GI-NET with elevated (\> ULN) biomarkers (serotonin, 5-hydroxyindoleacetic acid (5-HIAA), chromogranin A (CgA), neurokinin A, and neuron-specific enolase (NSE)) * Life expectancy \> 12 weeks * Must have received or may still be receiving one or more therapies including octreotide or serotonin synthesis inhibitor (SSI) or other somatostatin analogues * Confirmed progressive disease within 18 months of enrollment on study * Recovered from prior radiation therapy or surgery * Eastern Cooperative Oncology Group (ECOG) performance score 0-2 * Absolute neutrophil count (ANC) ≥ 1,500/µL (without growth factors) * Platelet count ≥ 100,000/µL * Adequate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL (177 µmol/L) * Adequate hepatic function: serum total bilirubin ≤ 2X greater than the upper limit of normal (ULN) (≤ 3X ULN in subjects with liver metastases), aspartate aminotransferase) AST) / alanine aminotransferase (AST) ≤ 2X the ULN for the local reference lab (≤ 5X the ULN for subjects with liver metastases) * Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide imaging or other imaging modality) * Women of childbearing potential as well as fertile men and their partners must use an effective method of birth control
Exclusion criteria
* Inadequately controlled hypertension defined as BP \> 150/100 mm Hg despite medication * Prior history of hypertensive crisis or hypertensive encephalopathy * Recent history (within 6 months of start of screening) of unstable angina pectoris pattern, myocardial infarction (including non-Q wave MI), or NYHA (New York Heart Association) Class III and IV Congestive Heart Failure (CHF) * Subjects who have clinical evidence of carcinoid-induced heart disease * History of prior cerebrovascular accident (CVA), including transient ischemic attach (TIA) * Known central nervous system (CNS) disease except for treated brain metastasis * History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (\<60 bpm), heart block (excluding 1st degree block, being PR interval prolongation only), congenital long QT syndrome or new ST segment elevation or depression or new Q wave on ECG * Corrected QT interval (QTc) \> 480 msec * Ongoing treatment with any drugs known to prolong the QTc interval, including anti-arrhythmic medications (stable regimen of antidepressants of the selective serotonin reuptake inhibitor (SSRI) class is allowed)) * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * Significant vascular disease or recent peripheral arterial thrombosis * Known intolerance of or hypersensitivity to fosbretabulin * History of solid organ transplant or bone marrow transplant * Any other intercurrent medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results * High grade or poorly differentiated NET * NET tumor other than PNET or GI-NET * No elevated biomarker (\>ULN) that can be followed * Received regional hepatic infusion therapy within 6 months of enrollment (RFA allowed \>6 months prior to enrollment)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Baseline and 4 months | The mean change from baseline in chromogranin A (CgA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%. |
| Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Baseline and 4 months | The mean change from baseline in 5-hydroxyindoleacetic acid (5-HIAA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%. |
| Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Baseline and 4 months | The mean change from baseline in serotonin biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1 | Baseline and 4 months | The objective response rate (complete response, partial response, progressive disease, or stable disease) was determined by the investigator assessment of the participant's CT or MRI using Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) for target lesions. Partial Response (PR) is when there is at least 30% decrease in sum of the longest diameter of the target lesions. Progressive Disease (PD) is when there is at least 20% increase in the sum of the longest diameter of the target lesions, as well as an absolute increase of at least 5 mm (including appearance of new lesions). Stable Disease (SD) is when there neither a PR nor PD is noted. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Fosbretabulin Tromethamine Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
fosbretabulin tromethamine: 60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity | 18 |
| Total | 18 |
Baseline characteristics
| Characteristic | Fosbretabulin Tromethamine |
|---|---|
| Age, Continuous | 57.8 years STANDARD_DEVIATION 9.28 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 16 Participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 18 |
| other Total, other adverse events | 18 / 18 |
| serious Total, serious adverse events | 2 / 18 |
Outcome results
Primary
Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline
The mean change from baseline in 5-hydroxyindoleacetic acid (5-HIAA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%.
Time frame: Baseline and 4 months
Population: Participants who had 5-hydroxyindoleacetic acid (5-HIAA) biomaker sample taken at baseline and at 4 months.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Improved | 2 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Stable | 8 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Worsened | 3 Participants |
Primary
Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline
The mean change from baseline in chromogranin A (CgA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%.
Time frame: Baseline and 4 months
Population: Safety Population
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Improved | 1 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Stable | 11 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Worsened | 6 Participants |
Primary
Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline
The mean change from baseline in serotonin biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%.
Time frame: Baseline and 4 months
Population: Participants who had serotonin biomaker samples taken at baseline and at 4 months.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Improved | 0 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Stable | 10 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Worsened | 2 Participants |
Secondary
Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1
The objective response rate (complete response, partial response, progressive disease, or stable disease) was determined by the investigator assessment of the participant's CT or MRI using Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) for target lesions. Partial Response (PR) is when there is at least 30% decrease in sum of the longest diameter of the target lesions. Progressive Disease (PD) is when there is at least 20% increase in the sum of the longest diameter of the target lesions, as well as an absolute increase of at least 5 mm (including appearance of new lesions). Stable Disease (SD) is when there neither a PR nor PD is noted.
Time frame: Baseline and 4 months
Population: Modified Intent-to-Treat
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Fosbretabulin Tromethamine | Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1 | Partial Response | 1 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1 | Stable Disease | 7 Participants |
| Fosbretabulin Tromethamine | Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1 | Progressive Disease | 6 Participants |